Tasly Pharmaceutical Group Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Tasly Pharmaceutical Group Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Tasly Pharmaceutical Group Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Tasly Pharmaceutical Group Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Tasly Pharmaceutical Group Co Ltd (Tasly) manufactures and distributes chemical medicine, biological medicine, healthcare products, traditional Chinese medicine (TCM), functional food, and other products. The company's product line includes herbal medicine, chemical medicine, prescription drugs, pharmaceutical substances, health products, active pharmaceutical ingredients (APIs), herbal extract, tea, cosmetics, daily hygiene product series, and medical equipment. Its products serve the various therapy areas such as cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological. Tasly markets its products in China's domestic market through a dedicated direct sales force supplying hospitals and pharmacies, also in international markets through regional subsidiaries, branch offices, and joint-venture networks across the US, the Netherlands, Russia, Türkiye, South Korea, Indonesia, Malaysia, Vietnam, Thailand, Pakistan, South Africa, Nigeria, Ghana, Kenya, Botswana, and Zambia." Tasly is headquartered in Tianjin, China.
Headquarters
China
Address
No. 2, Pujihe East Road, Tianjin, 300410
Website
www.taslypharma.com
Telephone
86 222 6736290
No of Employees
10,563
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600535 (SHA)
Revenue (2024)
$1.1B
-3.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
15.6%
(2024 vs 2023)
Market Cap*
$3.1B
Net Profit Margin (2024)
XYZ
19.4%
(2024 vs 2023)
* As of and is in US$
Tasly Pharmaceutical Group Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Cardiovascular and Cerebrovascular: |
| Compound Danshen Dripping Pills |
| Xingnaojing Zhusheye |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Stake Sale | In March, the company sold its 28% stake to China Resources Sanjiu Medical & Pharmaceutical for US$869 million. |
| 2024 | Others | In June, the company's joint venture Tasly Mauna Kea Medical Engineering Technology secured the class II medical device business license in China. |
| 2023 | Contracts/Agreements | In October, the company and Huawei Cloud Computing Technology Co entered into a cooperation agreement to integrate traditional Chinese medicine characteristic data and the basic capabilities of the Pangu large model. |
Competitor Comparison
| Key Parameters | Tasly Pharmaceutical Group Co Ltd | Sinopharm Group Co Ltd | Shanghai Pharmaceuticals Holding Co Ltd | China National Accord Medicines Corporation Ltd | Shandong Buchang Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Tianjin | Shanghai | Shanghai | Shenzhen | Heze |
| State/Province | Tianjin | Shanghai | Shanghai | Guangdong | Shandong |
| No. of Employees | 10,563 | 94,910 | 49,608 | 28,336 | 7,237 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Zhou Hui | Chairman | Executive Board | 2025 | 55 |
| Cai Jinyong | Director; General Manager | Executive Board | 2025 | 54 |
| Xi Kai | Deputy Party Secretary; Director - Employee | Senior Management | 2025 | 49 |
| Ju Aichun | Deputy General Manager | Senior Management | 2025 | 53 |
| Yu Jie | Secretary; Deputy General Manager | Senior Management | 2025 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer